4.5 Review

Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer

期刊

LUNG CANCER
卷 76, 期 1, 页码 19-25

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2011.10.018

关键词

Circulating tumour cells (CTCs); Circulating tumour microemboli (CTM); Non-small cell lung cancer; Small cell lung cancer; Biomarker; Liquid biopsy; Metastasis; Epithelial mesenchymal transition (EMT)

向作者/读者索取更多资源

Circulating tumour cells (CTCs) have attracted much recent interest in cancer research as a potential biomarker and as a means of studying the process of metastasis. It has long been understood that metastasis is a hallmark of malignancy, and conceptual theories on the basis of metastasis from the nineteenth century foretold the existence of a tumour seed which is capable of establishing discrete tumours in the soil of distant organs. This prescient seed and soil hypothesis accurately predicted the existence of CTCs; microscopic tumour fragments in the blood, at least some of which are capable of forming metastases. However, it is only in recent years that reliable, reproducible methods of CTC detection and analysis have been developed. To date, the majority of studies have employed the CellSearch (TM) system (Veridex LLC), which is an immunomagnetic purification method. Other promising techniques include microfluidic filters, isolation of tumour cells by size using microporous polycarbonate filters and flow cytometry-based approaches. While many challenges still exist, the detection of CTCs in blood is becoming increasingly feasible, giving rise to some tantalizing questions about the use of CTCs as a potential biomarker. CTC enumeration has been used to guide prognosis in patients with metastatic disease, and to act as a surrogate marker for disease response during therapy. Other possible uses for CTC detection include prognostication in early stage patients, identifying patients requiring adjuvant therapy, or in surveillance, for the detection of relapsing disease. Another exciting possible use for CTC detection assays is the molecular and genetic characterization of CTCs to act as a liquid biopsy representative of the primary tumour. Indeed it has already been demonstrated that it is possible to detect HER2, KRAS and EGER mutation status in breast, colon and lung cancer CTCs respectively. In the course of this review, we shall discuss the biology of CFCs and their role in metastagenesis, the most commonly used techniques for their detection and the evidence to date of their clinical utility, with particular reference to lung cancer. (C) 2012 Published by Elsevier Ireland Ltd.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据